Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

Moviefone speaks with Lucy Liu and Chris Sullivan about Steven Soderbergh's 'Presence'. "It was really a dream come true working with Steven," Liu said. Moviefone recently had the pleasure of ...

“There’s something very corrosive about what’s happening within this family,” says Liu. “Corrosion is not something that you necessarily see. It’s something you see after the fac ...

In the psychological thriller “Presence,” Lucy Liu plays a mother whose family discovers that their house is being haunted by a ghost. Speaking about the film, she said she is open to the ...

At this point, they'll want to defeat any enemy officers that are attacking Liu Bei and then make their way north toward the Wei forces, taking out any officers they encounter along the way.

"Presence" lands in theaters Jan. 24. Lucy Liu turned heads at the New York premiere of her film "Presence" on Thursday night, dazzling in an ethereal black tulle gown from Zuhair Murad's Fall ...

Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of Obesity—but not GLP-1s At JPM25 on Monday, GSK Chief Scientific ...

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.